841 related articles for article (PubMed ID: 25398832)
1. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Rodon P; Hulin C; Pegourie B; Tiab M; Anglaret B; Benboubker L; Jardel H; Decaux O; Kolb B; Roussel M; Garderet L; Leleu X; Fitoussi O; Chaleteix C; Casassus P; Lenain P; Royer B; Banos A; Benramdane R; Cony-Makhoul P; Dib M; Fontan J; Stoppa AM; Traullé C; Vilque JP; Pétillon MO; Mathiot C; Dejoie T; Avet-Loiseau H; Moreau P
Haematologica; 2015 Feb; 100(2):e56-9. PubMed ID: 25398832
[No Abstract] [Full Text] [Related]
2. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
[No Abstract] [Full Text] [Related]
3. Bendamustine: the remedy that came in from the cold.
Lentzsch S
Blood; 2014 Feb; 123(7):948-50. PubMed ID: 24526773
[No Abstract] [Full Text] [Related]
4. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Ludwig H; Kasparu H; Leitgeb C; Rauch E; Linkesch W; Zojer N; Greil R; Seebacher A; Pour L; Weißmann A; Adam Z
Blood; 2014 Feb; 123(7):985-91. PubMed ID: 24227817
[TBL] [Abstract][Full Text] [Related]
5. What is the correct philosophy for the treatment of multiple myeloma?
Gertz MA
Leuk Lymphoma; 2007 Dec; 48(12):2298-9. PubMed ID: 18066999
[No Abstract] [Full Text] [Related]
6. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
Fenk R; Michael M; Zohren F; Graef T; Czibere A; Bruns I; Neumann F; Fenk B; Haas R; Kobbe G
Leuk Lymphoma; 2007 Dec; 48(12):2345-51. PubMed ID: 18067009
[TBL] [Abstract][Full Text] [Related]
7. Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
Mele G; Giannotta A; Pinna S; Loseto G; Coppi MR; Brocca CM; Melpignano A; Quarta G
Leuk Lymphoma; 2010 May; 51(5):937-40. PubMed ID: 20350279
[No Abstract] [Full Text] [Related]
8. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yellin O; Bessudo A; Boccia RV; Noga SJ; Gravenor DS; Patel-Donnelly D; Siegel RS; Kewalramani T; Gorak EJ; Nassir Y; Swift RA; Mayo D
Br J Haematol; 2013 Feb; 160(3):321-30. PubMed ID: 23150919
[TBL] [Abstract][Full Text] [Related]
9. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Dimopoulos MA; Orlowski RZ; Facon T; Sonneveld P; Anderson KC; Beksac M; Benboubker L; Roddie H; Potamianou A; Couturier C; Feng H; Ataman O; van de Velde H; Richardson PG
Haematologica; 2015 Jan; 100(1):100-6. PubMed ID: 25261096
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
11. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Pönisch W; Bourgeois M; Moll B; Heyn S; Jäkel N; Wagner I; Rohrberg R; Hurtz HJ; Schmalfeld M; Aßmann M; Edelmann T; Mohren M; Hoffmann FA; Becker C; Schwarzer A; Schönfelder U; Zehrfeld T; Hensel G; Löschcke K; Krahl R; Ali HA; Niederwieser D
J Cancer Res Clin Oncol; 2013 Mar; 139(3):499-508. PubMed ID: 23184429
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.
Chim CS; Wong KY
Bone Marrow Transplant; 2014 Dec; 49(12):1545-7. PubMed ID: 25133896
[No Abstract] [Full Text] [Related]
13. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
[TBL] [Abstract][Full Text] [Related]
14. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Leleu X; Attal M; Arnulf B; Moreau P; Traulle C; Marit G; Mathiot C; Petillon MO; Macro M; Roussel M; Pegourie B; Kolb B; Stoppa AM; Hennache B; Bréchignac S; Meuleman N; Thielemans B; Garderet L; Royer B; Hulin C; Benboubker L; Decaux O; Escoffre-Barbe M; Michallet M; Caillot D; Fermand JP; Avet-Loiseau H; Facon T;
Blood; 2013 Mar; 121(11):1968-75. PubMed ID: 23319574
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma, version 1.2013.
Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Illizaliturri F; Huff CA; Kassim A; Krishnan AY; Liedtke M; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Weber D; Yahalom J; Yunus F; Shead DA; Kumar R
J Natl Compr Canc Netw; 2013 Jan; 11(1):11-7. PubMed ID: 23307977
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
18. Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.
Zhang Y; Liu H; Chen X; Bai Q; Liang R; Shi B; Liu L; Tian D; Liu M
Pathol Oncol Res; 2014 Oct; 20(4):987-95. PubMed ID: 24942506
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
[TBL] [Abstract][Full Text] [Related]
20. Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Baz R; Miladinovic B; Patel A; Ho VQ; Shain KH; Alsina M; Nishihori T; Ochoa-Bayona JL; Sullivan DM; Dalton WS; Djulbegovic B
Leuk Res; 2013 Sep; 37(9):1077-82. PubMed ID: 23809054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]